The 2022 OncoAlert Colloquium Day 5: GI Oncology

The 2022 OncoAlert Colloquium Day 4: ESGO Sessions and Gynaecological Oncology

The 2022 OncoAlert Colloquium Day 3: Lung Cancer

The 2022 OncoAlert Colloquium Day 2: GU Oncology

The 2022 OncoAlert Colloquium Day 1: Breast Cancer

NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy in locally advanced rectal cancer

NIVO + chemo and NIVO + IPI continue to demonstrate clinically meaningful survival benefit vs chemo for advanced ESCC

ASH 2022: Multiple myeloma roundup

Consolidation therapy with blinatumomab improves OS in newly diagnosed patients with B-Lineage ALL in MRD negative remission

Trastuzumab deruxtecan shows greater OS compared to trastuzumab emtansine in patients with HER2 + mBC

Mosunetuzumab monotherapy demonstrates durable efficacy with a manageable safety profile in R/R follicular lymphoma

Polatuzumab vedotin combined with R-ICE as second-line therapy gives favourable results against R/R diffuse large B-cell lymphoma